Abstract: Provided is a pharmaceutical composition including irinotecan free base. The pharmaceutical composition according to the presently claimed subject matter enables the effective oral administration of irinotecan and as such, can increase the convenience of administration of irinotecan and provide a high in vivo absorption rate, compared to conventional injections.
Type:
Application
Filed:
June 12, 2020
Publication date:
October 6, 2022
Applicant:
DAE HWA PHARMA. CO., LTD.
Inventors:
Jun-Hee JANG, In-Hyun LEE, Min-Hee SON, Hye-Jin PARK
Abstract: Provided is a pharmaceutical composition for oral administration in the form of powder obtained by a process including: (a) preparing an emulsion including zanamivir as an active ingredient; triglyceride; acyl glycerol; a nonionic surfactant; a sugar; and water; and (b) lyophilizing the emulsion prepared in the step (a). The pharmaceutical composition according to the presently claimed subject matter can significantly increase in vivo absorption rate of zanamivir. Further, the pharmaceutical composition according to the presently claimed subject matter is in the form of powder, which not only make it easy to store and distribute but also make it possible to avoid the use of functional packaging materials for preventing changes in moisture.
Type:
Application
Filed:
June 12, 2020
Publication date:
September 22, 2022
Applicant:
DAE HWA PHARMA. CO., LTD.
Inventors:
Jun-Hee JANG, In-Hyun LEE, Min-Hee SON, Hye-Jin PARK
Abstract: Provided is a pharmaceutical composition for oral administration, including (a) a taxane, (b) a medium chain triglyceride, (c) an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, (d) a surfactant, and optionally (e) polyoxyl glyceryl fatty acid ester and a process for preparing the same.
Type:
Grant
Filed:
April 10, 2020
Date of Patent:
September 14, 2021
Assignee:
DAE HWA PHARMA. CO., LTD.
Inventors:
In-Hyun Lee, Min-Hee Son, Yeong-Taek Park, Seul-Ae Lee, Han-Koo Lee
Abstract: The present invention provides a pharmaceutical composition for oral administration, comprising (a) 4 to 40% by weight of a taxane, (b) 10 to 30% by weight of a medium chain triglyceride, (c) 30 to 70% by weight of monooleoyl glycerol, (d) 5 to 30% by weight of a surfactant, and (e) 10 to 30% by weight of polyoxyl glyceryl fatty acid ester and a process for preparing the same.
Type:
Grant
Filed:
April 6, 2016
Date of Patent:
June 1, 2021
Assignee:
DAE HWA PHARMA. CO., LTD.
Inventors:
In-Hyun Lee, Min-Hee Son, Yeong-Taek Park, Han-Koo Lee
Abstract: The present invention provides a pharmaceutical composition for oral administration, consisting essentially of (a) 4 to 40% by weight of a taxane, (b) 10 to 40% by weight of polyoxyl glyceryl fatty acid ester, (c) 30 to 70% by weight of monooleoyl glycerol or 30 to 70% by weight of an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, and (d) 5 to 30% by weight of a surfactant and a process for preparing the same.
Type:
Grant
Filed:
April 6, 2016
Date of Patent:
April 27, 2021
Assignee:
DAE HWA PHARMA. CO., LTD.
Inventors:
In-Hyun Lee, Min-Hee Son, Yeong-Taek Park, Han-Koo Lee
Abstract: Provided is a pharmaceutical composition for oral administration, including (a) a taxane, (b) a medium chain triglyceride, (c) an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, (d) a surfactant, and optionally (e) polyoxyl glyceryl fatty acid ester and a process for preparing the same.
Type:
Application
Filed:
April 10, 2020
Publication date:
July 30, 2020
Applicant:
DAE HWA PHARMA. CO., LTD.
Inventors:
In-Hyun LEE, Min-Hee SON, Yeong-Taek PARK, Seul-Ae LEE, Han-Koo LEE
Abstract: Provided is a pharmaceutical composition for oral administration, including (a) a taxane, (b) a medium chain triglyceride, (c) an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, (d) a surfactant, and optionally (e) polyoxyl glyceryl fatty acid ester and a process for preparing the same.
Type:
Grant
Filed:
July 30, 2015
Date of Patent:
May 19, 2020
Assignee:
DAE HWA PHARMA. CO., LTD.
Inventors:
In-Hyun Lee, Min-Hee Son, Yeong-Taek Park, Seul-Ae Lee, Han-Koo Lee
Abstract: The present invention provides a pharmaceutical composition for oral administration, consisting essentially of (a) 4 to 40% by weight of a taxane, (b) 10 to 40% by weight of polyoxyl glyceryl fatty acid ester, (c) 30 to 70% by weight of monooleoyl glycerol or 30 to 70% by weight of an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, and (d) 5 to 30% by weight of a surfactant and a process for preparing the same.
Type:
Application
Filed:
April 6, 2016
Publication date:
March 19, 2020
Applicant:
DAE HWA PHARMA. CO., LTD.
Inventors:
In-Hyun LEE, Min-Hee SON, Yeong-Taek PARK, Han-Koo LEE
Abstract: The present invention provides a pharmaceutical composition or a food composition comprising, as active ingredients, flavone-6-C-glucose derivatives or galenical extracts containing flavone-6-C-glucose derivatives. The composition of the present invention shows a functional effect of effectively treating or preventing cognitive dysfunction disorders such as delirium, dementia or amnesia, stroke, palsy, attention disorders, anxiety disorders or sleep disorders.
Type:
Grant
Filed:
August 14, 2014
Date of Patent:
April 9, 2019
Assignee:
DAE HWA PHARMA CO., LTD.
Inventors:
Jong Hoon Ryu, Jae Hoon Cheong, Chan Young Shin, Dae Sik Jang, Hyung Eun Lee, Hyun Ji Kim, Byeol Ryu, In Ho Jung, Yeong Woo Jo
Abstract: The present invention provides a pharmaceutical composition for oral administration, comprising (a) 4 to 40% by weight of a taxane, (b) 10 to 30% by weight of a medium chain triglyceride, (c) 30 to 70% by weight of monooleoyl glycerol, (d) 5 to 30% by weight of a surfactant, and (e) 10 to 30% by weight of polyoxyl glyceryl fatty acid ester and a process for preparing the same.
Type:
Application
Filed:
April 6, 2016
Publication date:
January 3, 2019
Applicant:
DAE HWA PHARMA. CO., LTD.
Inventors:
In-Hyun LEE, Min-Hee SON, Yeong-Taek PARK, Han-Koo LEE
Abstract: The pharmaceutical composition of the present invention, which comprises spinosin or a spinosin-containing herbal extract, is a composition for preventing and treating cognitive function disorders, and can effectively improve memory and learning ability, and effectively treat and prevent cognitive function disorders such as dementia and amnesia.
Type:
Grant
Filed:
November 3, 2016
Date of Patent:
May 1, 2018
Assignees:
MINISTRY OF FOOD AND DRUG SAFETY, DAE HWA PHARMA, CO., LTD.
Inventors:
Jong Hoon Ryu, Hyung Eun Lee, Sam Sik Kang, Ju Sun Kim, So Young Lee, Do Hoon Kim, Dong Sup Kim, Seung Hee Kim
Abstract: Provided is a pharmaceutical composition for oral administration, including (a) a taxane, (b) a medium chain triglyceride, (c) an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, (d) a surfactant, and optionally (e) polyoxyl glyceryl fatty acid ester and a process for preparing the same.
Type:
Application
Filed:
July 30, 2015
Publication date:
November 2, 2017
Applicant:
DAE HWA PHARMA. CO., LTD.
Inventors:
In-Hyun LEE, Min-Hee SON, Yeong-Taek PARK, Seul-Ae LEE, Han-Koo LEE